Therapy Optimization in Multiple Sclerosis (MS)

Completed

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.

Key facts

Study ID

NCT00819000

Run by

Teva Neuroscience, Inc.

People needed

2878

Starts

2008-12-01

Expected to finish

2013-01-01

Last updated by the study team

2013-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, 18 years of age or older, with a diagnosis of MS.
• Being treated with Glatiramer Acetate (GA) or (IFN)-β
• Receiving therapy from a participating Specialty Pharmacy

You may not qualify if…

• Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study
• Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)
• Unlikely to be able to participate for the full two years of the study

Where it is running

• Teva Investigational Site — Swartz Creek, Michigan, United States
• Teva Investigational Site — Columbus, Ohio, United States
• Teva Investigational Site — Carnegie, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.